Physiological and immunohistochemical characterization of cisplatin- induced neuropathy in mice

Muscle and Nerve

Volumn 22, Issue 3, 1999, Pages 329-340

  Verdú, Enrique ^a   Vilches, Jorge J ^a   Rodríguez, Francisco J ^a   Ceballos, Dolores ^a   Valero, Antoni ^a   Navarro, Xavier ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Cisplatin; Electrophysiology; Immunohistochemistry; Motor function sensory function; Neuropathy; Skin; Sudomotor

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CISPLATIN; GENE PRODUCT; NEUROPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROPHYSIOLOGY; FEMALE; FOOT PAD; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE FUNCTION; NEUROPATHY; NEUROSECRETION; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSORY NERVE CONDUCTION; SKIN BIOPSY; SWEATING; TIBIAL NERVE;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITONIN GENE-RELATED PEPTIDE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; IMMUNOHISTOCHEMISTRY; MICE; MOTOR ACTIVITY; NERVOUS SYSTEM DISEASES; NOCICEPTORS; SWEATING; THIOLESTER HYDROLASES; UBIQUITIN THIOLESTERASE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033010359     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199903)22:3<329::AID-MUS5>3.0.CO;2-8     Document Type: Article

References (49)

1. Apfel SC, Arezzo JC, Lipson L, Kessler JA. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992;31:76-80.
2. Barajon I, Bersani M, Quartu M, Del Fiacco M, Cavaletti G, Holst JJ, Tredici G. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 1996;138:93-104.
3. Beokelheide K, Arcila ME, Eveleth J. Cis-diamminedichloroplatinum (II) (cisplatin) alters microtubule assembly dynamics. Toxicol Appl Pharmacol 1992;116:146-151.
4. Boogerd W, ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJJF, van der Sande JJ. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neuro-oncol 1990;9:255-263.
5. Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli MR, Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992;69:203-207.
6. Cavaletti G, Petruccioli MG, Tredici G, Marmiroli P, Barajon I, Fabbrica D, Di Francesco A. Effects of repeated administration of low doses of cisplatin on the rat nervous system. Int J Tissue React 1991;13:151-157.
7. Cavaletti G, Tredici G, Marmiroli P, Fabbrica D, Braga M. Off-treatment course of cisplatin-induced dorsal root ganglia neuronopathy in rats. In vivo 1994;8:313-316.
8. Cavaletti G, Tredici G, Marmiroli P, Petrucciolo MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol 1992;84:364-371.
9. Cohen SC, Mollman JE. Cisplatin-induced gastric paresis. J Neurol Oncol 1987;5:237-240.
10. Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cisplatin. Acta Neurol Scand 1987;76:86-93.
11. De Koning P, Neijt JP, Jennekens FGI, Gispen WH. Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 1987;89:81-87.
12. Gao W-Q, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller F, Phillips HS, Winslow JW. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995;38:30-37.
13. Gerritsen van der Hoop R, Hamers FPT, Neijt JP, Veldman H, Gispen WH, Jennekens FGI. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 1994;126:109-115.
14. Gibbins IL, Furness JB, Costa M, Macintyre I, Hillard CJ, Gingi S. Co-localization of calcitonin gene-related peptide immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. Neurosci Lett 1985; 57:125-130.
15. Gregg RW, Mopelo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10:795-803.
16. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH. Reduced glutathione protects against cisplatin-induced neurotoxity in rats. Cancer Res 1993;53:544-549.
17. Hargreaves K, Dubner R, Brown F, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:77-88.
18. Hilkens PHE, Pronk LC, Verweij J, Vecht CJ, van Putten WLJ, van der Bent MJ. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 1997;75:417-422.
19. Hoffman PN, Cleveland DW, Griffin JW, Landers PW, Cowan NJ, Price DL. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci USA 1987;84: 3472-3476.
20. Ishida-Yamamoto A, Senba E. Cell types and axonal sizes of calcitonin gene-related peptide-containing primary sensory neurons of the rat. Brain Res Bull 1990;24:759-764.
21. Kennedy WR, Sakuta M. Collateral reinnervation of sweat glands. Ann Neurol 1984;15:73-78.
22. Kennedy WR, Sakuta M, Sutherland D, Goetz FC. Quantitation of the sweating deficiency in diabetes mellitus. Ann Neurol 1984;15:482-488.
23. Kennedy WR, Wendelschafer-Crabb G. Utility of skin biopsy in diabetic neuropathy. Semin Neurol 1996;16:163-168.
24. Kennedy WR, Wendelschafer-Crabb G, Brelje T. Innervation and vasculature of human sweat glands. An immunohistochemisiry laser scanning confocal fluorescence microscopy study. J Neurosci 1994;14:6825-6833.
25. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, Krarup K. Examination of distal involvement in cisplatin-induced neuropathv in man. Brain 1993;116:1017-1041.
26. Landis SC, Fredieu JR. Coexistence of calcitonin gene-related peptide and vasoactive intestinal peptide in cholinergic sympathetic innervation of rat sweat glands. Brain Res 1986;377: 177-181.
27. Lee Y, Takami K, Kawai Y, Girgis S, Hillyard J, Macintyre I, Emson C, Tohyama C. Distribution of calcitonin gene-related peptide in the rat peripheral nervous system with reference to its coexistence with substance P. Neuroscience 1985;15: 1227-1237.
28. Levy DM, Terenghi G, Gu XH, Abraham RR, Springall DR, Polak JM. Immunohistochemical measurements of nerves and neuropeptides in diabetic skin: relationship to tests of neurological function. Diabetologia 1992;35:889-897.
29. McCarthy BG, Hsieh ST, Stocks A, Hauer P, Macko C, Cornblath DR, Griffin JW, McArthur JC. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995;45:1848-1855.
30. Mollman JE. Cisplatin neurotoxicity. N Engl J Med 1990;322: 126-127.
31. Müller LJ. Gerritsen van der Hoop R, Moorer-van Delft CM, Gispen WH, Roubos EW. Morphological and electrophysiological study of the effects of cisplatin and ORG-2766 on rat spinal ganglion neurons. Cancer Res 1990;50:2437-2442.
32. Navarro X, Kennedy WR. Changes in sudomotor nerve territories with aging in the mouse. J Auton Nerv Syst 1990;31: 101-108.
33. Navarro X, Verdú E, Butí M. Comparison of the regenerating and reinnervating capabilities of different functional types of nerve fibers. Exp Neurol 1994;129:217-224.
34. Navarro X, Verdú E, Guerrero J, Butí M, Gon̄alons E. Abnormalities of sympathetic sudomotor function in experimental acrylamide neuropathy. J Neurol Sci 1993;114:56-61.
35. Navarro X, Verdú E, Wendelschafer-Crabb G, Kennedy WR. Innervation of cutaneous structures in the mouse hindpaw: a confocal microscopy immunocytochemical study. J Neurosci Res 1995;41:111-120.
36. Navarro X, Verdú E, Wendelschafer-Crabb G, Kennedy WR. Immunohistochemical study of skin reinnervation by regenerative axons. J Comp Neurol 1997;380:164-174.
37. Povlsen B, Hildebrand C, Wiesenfeld-Hallin Z, Stankovic N. Functional projection of regenerated rat sural nerve axons to the hindpaw skin after sciatic nerve lesions. Exp Neurol 1993; 119:99-106.
38. Riggs JE, Ashraf M, Snyder RD, Gutmann L. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol 1988;23: 92-94.
39. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984;34:934-938.
40. Rosenfeld CS, Broder LE. Cisplatin-induced autonomie neuropathy. Cancer Treat Rep 1984;68:659-660.
41. Russell JW, Windebank AJ, McNiven MA, Brat DJ, Brimijoin WS. Effect of cisplatin and ACTH 4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res 1995;676:258-267.
42. Sala C, Andreose JS, Fumagalli G, Lømo T. Calcitonin generelated peptide: possible role in formation and maintenance of neuromuscular junctions. J Neurosci 1995;15:520-528.
43. Schmidt Y, Unger JW, Bartke I, Reiter R. Effect of nerve growth factor on peptide neurons in dorsal root ganglia after taxol or cisplatin treatment and in diabetic (db/db) mice. Exp Neurol 1995;132:16-23.
44. Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J. PGP 9.5 - a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983;278:224-228.
45. Thompson SW, Davis LAE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy: clinical electrophysiologic, morphologic and toxicologic studies. Cancer 1984;54:1269-1275.
46. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 1986;69: 295-308.
47. Verdú E, Navarro X. Comparison of immunohistochemical and functional reinnervation of skin and muscle after peripheral nerve injury. Exp Neurol 1997;146:187-198.
48. Verdú E, Butí M, Navarro X. Functional changes of the peripheral nervous system with aging in the mouse. Neurobiol Aging 1996;17:73-77.
49. Vilches JJ, Navarro X, Verdú E. Functional sudomotor responses to cholinergic agonists and antagonists in the mouse. J Auton Nerv Syst 1995;55:105-111.